A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
NCT00111007
Completed
The objectives of this study are to compare the anti-tumor activity as measured by Progression Free Survival (PFS) and tolerability of Sorafenib in combination with Paclitaxel and Carboplatin versus Paclitaxel and Carboplatin in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who progressed after receiving only one prior therapy containing Dacarbazine (DTIC) or Temozolomide (TMZ).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2014
Locations: Not set, Louisville, Kentucky
Conditions: Melanoma
Register for Updates
EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
NCT01485848
Completed
Primary Objectives: o Run-in Phase: Determine a dose of EP-100 at which the initial benefit/risk of paclitaxel combined with EP-100 can be studied. o Randomized Phase: Compare the anti-tumor effects of EP-100 combined with weekly paclitaxel versus paclitaxel alone in patients with ovarian cancer. Secondary Objectives: o Randomized Phase: Quantify any significant changes in the safety profile of weekly paclitaxel alone compared to the doublet combination of paclitaxel with EP-100. o Determine an... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/09/2014
Locations: Investigational Site Number 840007, Louisville, Kentucky
Conditions: Ovarian Cancer Recurrent
Register for Updates
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
NCT00084214
Completed
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2014
Locations: James Graham Brown Cancer Center - University Of Louisville, Louisville, Kentucky
Conditions: Melanoma
Register for Updates
Treatment With Pazopanib for Neoadjuvant Breast Cancer
NCT00849472
Completed
The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/30/2014
Locations: GSK Investigational Site, Jeffersonville, Kentucky +4 locations
Conditions: Neoplasms, Breast
Register for Updates
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology
NCT00596830
Terminated
Determine whether the addition of CP- 751,871 in combination with paclitaxel plus carboplatin prolongs survival in patients with locally advanced (Stage IIIB with pleural effusion) or metastatic (Stage IV or recurrent) NSCLC of non adenocarcinoma histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2013
Locations: Pfizer Investigational Site, Louisville, Kentucky +1 locations
Conditions: Carcinoma, Squamous Cell, Carcinoma, Adenosquamous, Carcinoma, Large Cell, Carcinoma, Non-Small-Cell Lung
Register for Updates
Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer
NCT00003591
Completed
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus paclitaxel in treating patients who have nonmetastatic, unresectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2013
Locations: Medical Center at Bowling Green, Bowling Green, Kentucky +6 locations
Conditions: Pancreatic Cancer
Register for Updates
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
NCT00828841
Completed
This study is testing the investigational drug, cetuximab, in combination with different chemotherapy drugs for lung cancer. The aim of the study is to determine which of the drug combinations looks most promising and should be tested further. The study will also look at what side effects may occur.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2013
Locations: Not set, Hazard, Kentucky +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer
NCT00147537
Completed
Phase 1b Dose Excalation/Expansion: Identify and characterize safety and tolerability of recommended phase 2 dose of CP-751,871 when administered with paclitaxel and carboplatin Phase 1b Erlotinib Extension: To characterize the safety and tolerability of CP751,871 when administered with paclitaxel, carboplatin and erlotinib. Phase 2: To test the efficacy of CP-751,871 combined with paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2013
Locations: Pfizer Investigational Site, Louisville, Kentucky +4 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
NCT00002662
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel is more effective than docetaxel for breast cancer. PURPOSE: Randomized phase III trial to study the effectiveness of paclitaxel or docetaxel in treating women with stage IIIB or metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/01/2013
Locations: James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky
Conditions: Breast Cancer
Register for Updates
A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer
NCT00583830
Completed
The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2013
Locations: Kentuckiana Cancer Institute, PLLC, Louisville, Kentucky
Conditions: Non Small Cell Lung Cancer
Register for Updates
Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer
NCT00544167
Completed
Sorafenib is being looked at in a number of solid tumor settings including breast cancer. This trial is designed as a pilot study to assess the safety and tolerability of a novel oral agent in combination with standard chemotherapy in the treatment of early stage node positive or otherwise high-risk breast cancer. If this should prove to be a tolerable regimen for patients, this would provide rationale for further studies in a larger randomized fashion.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/25/2013
Locations: Consultants in Blood Disorders and Cancer, Louisville, Kentucky
Conditions: Breast Cancer
Register for Updates
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
NCT00193596
Completed
In this randomized trial, we will investigate the activity and toxicity of two active regimens, gemcitabine/irinotecan and paclitaxel/carboplatin/Etoposide (both followed by ZD1839) in the first-line treatment of patients with carcinoma of unknown primary site.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2013
Locations: Graves-Gilbert Clinic, Bowling Green, Kentucky +1 locations
Conditions: Neoplasms, Unknown Primary
Register for Updates